An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms

Chemoresistance limits its clinical implementation for pancreatic ductal adenocarcinoma (PDAC). We previously generated an EGFR/HER2 targeted conjugate, dual-targeting ligand-based lidamycin (DTLL), which shows a highly potent antitumor effect. To overcome chemoresistance in PDAC, we aim to study DT...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Hongjuan, Song, Wenping, Cao, Rui, Ye, Cheng, Zhang, Li, Chen, Hebing, Wang, Junting, Shi, Yuchen, Li, Rui, Li, Yi, Liu, Xiujun, Zhou, Xiaofei, Shao, Rongguang, Li, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489697/
https://www.ncbi.nlm.nih.gov/pubmed/36127339
http://dx.doi.org/10.1038/s41467-022-33037-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489697/
https://www.ncbi.nlm.nih.gov/pubmed/36127339
http://dx.doi.org/10.1038/s41467-022-33037-x

Ejemplares similares